BEARINGPOINT
6.2.2024 08:01:31 CET | Business Wire | Press release
Management and technology consultancy BearingPoint reports full-year revenues of €1.017 billion for 2023, a jump in year-on-year growth of 18%. The firm saw its bookings grow by 21% and delivered more than 1,800 projects in 32 countries. To support its growth, BearingPoint increased its workforce by 15% to more than 6,000 employees at the end of the year. For 2024, BearingPoint plans to hire more than 1,600 people as it accelerates its strategy and continues to expand globally.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240205345183/en/
Kiumars Hamidian, Managing Partner of BearingPoint. (Photo: Business Wire)
“2023 was a breakout year for BearingPoint,” said Kiumars Hamidian, Managing Partner of BearingPoint. “We reached our €1 billion in revenue target, and we did it sustainably, with a healthy growth position. We continue to see increasing demand for our services, especially our transformation programs and IP-driven digital assets. Growing demand is behind our expanding workforce, and we will continue strategic acquisitions in 2024 as we expand globally. I would like to thank all our amazing people and clients who made this success possible.”
Strategic acquisitions and global expansion
In 2023, BearingPoint completed five strategic acquisitions to enhance and strengthen its portfolio, particularly in the areas of sustainability (Korkia), Salesforce expertise (Smplicity), asset-backed securities (ABS) (TXS Securitization), and end-to-end services for IFS software and solutions through Arcwide, the joint venture of BearingPoint and IFS (bytics Group and Cedar Bay).
BearingPoint’s record hiring in 2023 was also due to expanding its expertise and services globally, especially in the US and China. In the US alone, BearingPoint achieved a revenue growth of 34%.
With more than 440 people and a strong revenue growth of 28%, the development of the Products business unit was another highlight for BearingPoint.
Continued investment in innovation, artificial intelligence and sustainability
BearingPoint continued to invest heavily in its innovative products and services and launched a generative AI hub, paving the way for businesses to unlock the transformative power of artificial intelligence. As one of the first consultancies BearingPoint published an ethical statement on the sustainable and responsible use of AI in cooperation with clients. The consultancy also set up an AI business task force early in 2023 and developed over 250 use cases last year. BearingPoint is delivering innovative solutions for its clients, including implementing a global GenAI vision for a top retail chain, creating an AI banking avatar for a large international bank, simplifying daily police work with an AI for a police department, and automating the creation of annual reports for an NGO.
BearingPoint has also supported many clients on their sustainability and decarbonization journeys, through integrated sustainability advisory and products as well as launching innovative new services including the BearingPoint Sustainability Maturity Assessment, the ESG Data Hub and the I Care Academy. BearingPoint has provided clients with streamlined ESG reporting support and enhanced sustainability transformation programs. Moreover, the firm invested more than 1,000 consulting days in CSR activities and ran numerous Climate Fresk workshops throughout the year.
People development is a top priority
In 2023, BearingPoint appointed 27 new Partners to the firm and promoted 1,398 people, the largest-ever cohort, reflecting the strength of the organization and its confidence in the future. BearingPoint made record investments in learning and people development and delivered an all-time-high of 260,000 training hours. BearingPoint provides a range of programs, such as Be.Oxford Academy, Be.School, Female Leadership, and the Yale Leadership Program. Over 2,200 people participated in these programs in 2023, a year which saw BearingPoint also open its Be.Campus in Brussels, where the firm will deliver even more trainings in 2024.
2024 – Strategy acceleration continues
In 2024, BearingPoint wants to outperform the market again and accelerate its strategy execution further, planing a double-digit organic revenue growth. In addition, the consultancy sees more strategic M&A activities and investments in developing its consulting and products portfolio in 2024, especially in focus areas such as sustainability and in key geographies such as the US. BearingPoint also said its joint venture Arcwide will continue to expand to become the IFS delivery partner of choice for enterprise organizations worldwide.
“As we look towards the future, BearingPoint is in an excellent position to grow and expand further. We are faithful to our values, empower people to succeed, and create lasting outcomes for our clients, society, and the planet,” said Kiumars Hamidian.
About BearingPoint
BearingPoint is an independent management and technology consultancy with European roots and a global reach. The company operates in three business units: Consulting, Products, and Capital. Consulting covers the advisory business with a clear focus on selected business areas. Products provides IP-driven digital assets and managed services for business-critical processes. Capital delivers M&A and transaction services.
BearingPoint’s clients include many of the world’s leading companies and organizations. The firm has a global consulting network with more than 10,000 people and supports clients in over 70 countries, engaging with them to achieve measurable and sustainable success.
For more information, please visit:
Homepage: www.bearingpoint.com
LinkedIn: www.linkedin.com/company/bearingpoint
X: @BearingPoint
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240205345183/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom